Skip to content

A Prospective Study Comparing [18F]mFBG PET-CT to [123I]mIBG Scanning in Neuroblastoma

Status
Recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2022-501694-39-01
Acronym
PS22PET
Enrollment
58
Registered
2024-09-23
Start date
2024-11-12
Completion date
Unknown
Last updated
2025-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

(suspision on) Neuroblastoma

Brief summary

Detected skeletal lesions on [18F]mFBG PET-CT and [123I]mIBG scanning

Detailed description

Detected soft tissue lesions on [18F]mFBG and [123I]mIBG scanning, Radiation absorbed doses (mSv) for organs and tumour of [18F]mFBG imaging, Mean difference in number of detected lesions and limits of agreement, Cohen’s kappa, SUVmean for normal organs, SUVmax for tumour lesions

Interventions

DRUG[18F]meta-fluorobenzylguanidine

Sponsors

Princess Maxima Center For Pediatric Oncology
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
0 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
Detected skeletal lesions on [18F]mFBG PET-CT and [123I]mIBG scanning

Secondary

MeasureTime frame
Detected soft tissue lesions on [18F]mFBG and [123I]mIBG scanning, Radiation absorbed doses (mSv) for organs and tumour of [18F]mFBG imaging, Mean difference in number of detected lesions and limits of agreement, Cohen’s kappa, SUVmean for normal organs, SUVmax for tumour lesions

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026